Viatris Inc.

What they do

Viatris makes and sells generics (including complex products), off-patent iconic brands such as EFFEXOR and Viagra, and an expanding portfolio of innovative medicines, with more than 1,400 approved molecules. The company operates 27 manufacturing, packaging, and distribution sites with more than 30,000 employees, and is headquartered in the U.S. with global centers in Pittsburgh, Shanghai, and Hyderabad. It reports geographic segments in Developed Markets, Emerging Markets, JANZ (Japan, Australia, New Zealand), and Greater China.

Revenue drivers

• Brands — Branded medicines generated $2.42B of net sales in Q2 2026, up 6% reported, and are the larger of the two product categories.
• Generics — Generics, including complex products, contributed $1.33B in Q2 2026, up 3% reported, and supply a high-volume, lower-price portion of the portfolio.
• Developed Markets — The largest geographic segment at $2.19B in Q2 2026, up 4% reported, covering operations primarily in North America and Europe.
• Greater China — The fastest-growing segment at $713.8M in Q2 2026, up 21% reported and 16% operationally, versus declines in Emerging Markets and JANZ.

Recent performance

Second-quarter 2026 total revenues were $3.76B, up 5% reported and 3.5% operationally versus Q2 2025. U.S. GAAP net loss was $119M (loss per share of $0.10), while adjusted net earnings rose 11% to $808.5M and Adjusted EPS was $0.69. Adjusted EBITDA was $1.19B, up 10% reported and 8% operationally, and adjusted gross margin improved to 57.5% from 56.6%. U.S. GAAP net cash provided by operating activities was $381.8M for the quarter, versus $219.7M a year earlier. On a full-year basis, revenue has declined every year since 2021 ($17.81B) to $14.25B in 2025, and 2025 included a net loss of $3.51B.

Strategy

Management is executing an enterprise-wide strategic review alongside restructuring and cost-saving activities, with a stated goal of returning the base business to growth and delivering on its pipeline. Viatris has simplified the portfolio through divestitures, including women's healthcare (March 2024), the India API business (June 2024), and the OTC business (July 2024), while retaining rights to Viagra, Dymista, and select OTC products. The company is pursuing an innovative pipeline and reported five positive Phase 3 readouts in 2025, including an EFFEXOR long-term extension study supporting Japan approval. Capital allocation is balanced: roughly $550M was returned to shareholders in Q2 2026, including about $270M of share repurchases through early August, alongside debt reduction to a 2.9x gross leverage ratio. The company also announced the sale of global rights to Tyrvaya and received U.S. FDA approval of Gwyn Lo.

Risks

• Strategic initiative execution — The company may not realize the intended benefits of its enterprise-wide strategic review, and its restructuring activities may present significant challenges.
• Divestiture impact — Divestitures of the women's healthcare, India API, OTC, and Upjohn Distributor Markets businesses reduce revenue and carry execution and customer-relationship risk.
• Manufacturing and supply chain — Changes or difficulties at manufacturing facilities, including shutdowns, inspections, remediation, supply chain continuity, or inventory management, could disrupt the 27-site global network.
• Leverage and cash returns — Long-term debt was $11.61B at June 30, 2026 against $886.5M of cash, and the company's ability to pay dividends or repurchase shares is explicitly tied to its financial condition.

Outlook

Management raised 2026 financial guidance midpoints for all metrics after the second quarter, citing strong first-half results and confidence in the business. The company expects a more balanced operating environment in the second half of 2026 and remains focused on disciplined execution and investing behind future growth drivers. Full-year 2026 U.S. GAAP net cash provided by operating activities is estimated at $1.9B to $2.1B, with a midpoint of approximately $2.0B. Guidance excludes transaction-related and restructuring-related costs and acquired IPR&D for unsigned deals, which cannot be reasonably forecasted.